Fundraising FoxFlagship Ventures — Full Portfolio
10 tracked investments · listed companies and verified rows first
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in
Co-investorsARCH Venture PartnersThird Rock VenturesSamsara BioCapital
Denali Therapeutics develops therapeutics for neurodegenerative diseases.
BiotechHealthtechMedical DevicesSan Francisco, US
Marc Tessier-Lavigne(Founder)inAlexander O. Schuth(Executive Officer)inRyan J. Watts(President, Chief Executive Officer and Director)inCarole Ho(Executive Officer)inSteve E. Krognes(Director)inAlexander Schuth(Founder)
Co-investorsARCH Venture PartnersEcoR1 CapitalF-Prime CapitalForesite CapitalGV (Google Ventures)Flagship Pioneering
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsEcoR1 CapitalGV (Google Ventures)Sofinnova VenturesViking GlobalAtlas VentureDeerfield Management Company+2 more
Joule is a lightweight fitness tracker (about 1.5 grams) that attaches behind existing post-style earrings to measure heart rate, calories, and daily activity, syncing to a companion phone app over Bluetooth.
ConsumerHardwareWellness & Fitness
Co-investorsWaterloo Accelerator Centre
BiotechCambridge, US
Torben Straight Nissen(Executive Officer, Director)inJoanne Protano(Executive Officer)inDavid Epstein(Director)Harvey F. Lodish(Director)Michael Rosenblatt(Director)Roger Pomerantz(Director)in
Co-investorsFlagship PioneeringKendall Capital Partners
Seventh Sense develops face-based biometric authentication solutions that verify identity without storing facial data, serving organizations and individuals needing secure access control, document signing, and identity verification.
AI & Machine LearningCybersecurityDeep TechDigital HealthSingapore, SG
Ashish KushwahaSam TsuiVarun Chatterji
Co-investors500 GlobalFlagship PioneeringNewpath Partners
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Cambridge, US
Nancy Simonian(CEO)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
HealthtechLexington, US
Michael Cima, Ph.D.(Director)Rahul Dhanda(Senior Vice President, Corporate Development)inJohn McDonough(Chief Executive Officer)inTom Lowery, Ph.D.(Chief Scientific Officer)Michael Gibbs, Esq.(Vice President and General Counsel)Joanne Spadoro, Ph.D.(Chief Operating Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersArcus VenturesFlybridge Capital PartnersJohnson & Johnson Innovation – JJDCPolaris Partners+1 more
Tetraphase Pharmaceuticals was a Watertown, MA biopharmaceutical company developing novel tetracycline antibiotics, including its lead drug Xerava (eravacycline) for multidrug-resistant bacterial infections.
BiotechWatertown, US
Guy Macdonald(Director)inLarry Edwards(Executive Officer, Director)inMaria Stahl(Executive Officer)inChristopher Watt(Executive Officer)
BoardL. Patrick Gage(Director)Keith Maher(Director)
Co-investorsBay City CapitalF-Prime CapitalExcel Venture ManagementMediphase Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.